Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Queensland Health
Argus Health
Deloitte
Fuji
Julphar
Medtronic
QuintilesIMS
Federal Trade Commission

Generated: November 19, 2018

DrugPatentWatch Database Preview

TACLONEX Drug Profile

« Back to Dashboard

Which patents cover Taclonex, and when can generic versions of Taclonex launch?

Taclonex is a drug marketed by Leo Pharma As and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in TACLONEX is betamethasone dipropionate; calcipotriene hydrate. There are sixty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene hydrate profile page.

US Patents and Regulatory Information for TACLONEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate OINTMENT;TOPICAL 021852-001 Jan 9, 2006 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate SUSPENSION;TOPICAL 022185-001 May 9, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate SUSPENSION;TOPICAL 022185-001 May 9, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for TACLONEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate OINTMENT;TOPICAL 021852-001 Jan 9, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate SUSPENSION;TOPICAL 022185-001 May 9, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene hydrate OINTMENT;TOPICAL 021852-001 Jan 9, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TACLONEX
Drugname Dosage Strength RLD Date
➤ Subscribe Ointment 0.005%/0.064% ➤ Subscribe ➤ Try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Queensland Health
Argus Health
Deloitte
Fuji
Julphar
Medtronic
QuintilesIMS
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.